Journal of Endocrinological Investigation

, Volume 34, Issue 3, pp 180–184 | Cite as

Effects of long-term hormone replacement therapy: Results from a cohort study

  • S. S. Signorelli
  • S. Sciacchitano
  • M. Anzaldi
  • V. Fiore
  • S. Catanzaro
  • M. Simili
  • S. Neri
Original Articles


The positive effects of hormonal replacement therapy (HRT) in protecting the cardiovascular system in women have been supported by several observational studies, while also being questioned by other randomized controled trials. Today, it is unclear whether HRT plays a crucial role, or even whether there is any role at all, for this therapy in preventing or in lowering cardiovascular disease (CVD). In the present study, we have evaluated the effectiveness of long-term HRT in post-menopausal women on the incidence of cardiovascular events and arterial remodeling, as well as on some metabolic factors. Eighty-four post-menopausal women (mean age: 46.3±5.2; age range: 42–66 yr) underwent HRT for 10.9±1.2 yr (range: 8–12 yr). None of these subjects showed new cardiovascular events, and we found a reduction of the intima-media thickness (baseline: 1.39±0.2, 1.35±0.2, 1.31 ±0.2 mm) and total cholesterol, LDL and antithrombin III levels were lower, while HDL and fibrinogen levels increased. The study highlights a number of positive effects both on vascular conditions and metabolic and coagulative markers that are usually considered as generic and crucial risk factors for CVD. The relatively low number of patients is perhaps a limitation of this study, however, the long-term period of follow-up should be considered an interesting and important factor. Furthermore, this study underlines the real-life clinical experience of a Menopause Center.


Post-menopause HRT cardiovascular events risk factors intima media thickness 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mosca L, Grundy SM, Judelson D, et al. Guide to Preventive Cardiology for Women. AHA/ACC Scientific Statement Consensus panel statement. Circulation 1999, 99: 2480–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Iniziative randomized controlled trial. JAMA 2004, 291: 1701–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progesti for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998, 280: 605–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Herrington DM, Brosmihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001, 56: 4216–22.CrossRefGoogle Scholar
  5. 5.
    Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001, 21: 1512–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Hwang J, Mack WJ, Xiang M, Sevanian A, Lobo RA, Hodis HN. Long-term effect of estrogen replacement on plasma nitric oxide levels: results from the estrogen in the prevention of atherosclerosis trial (EPAT). Atherosclerosis 2005, 18: 375–80.CrossRefGoogle Scholar
  7. 7.
    Arnal JF, Doiun-Echinard V, Tremollièrs F, et al. Understanding the controversy about hormonal replacement therapy: insights from estrogen effects on experimental and clinical atherosclerosis. Arch Mal Coeur Vaiss 2007, 100: 554–62.PubMedGoogle Scholar
  8. 8.
    Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 135: 939–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Creatsas G, Christodoulakos G, Lambrinoudaki I. Cardiovascular disease: screening and management of the a-symptomatic high-risk post-menopausal woman. Maturitas 2005, 52(Suppl 1): S32–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Signorelli SS, Neri S, Sciacchitano S, et al. Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. Maturitas 2006, 53: 77–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001, 75: 898–915.PubMedCrossRefGoogle Scholar
  12. 12.
    Best PJ, Berger PB, Miller VM, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998, 128: 285–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study, Hypertension 1995, 25: 848–53.Google Scholar
  14. 14.
    Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998, 98: 1158–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994, 24: 1757–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Borgfeldt C, Li C, Samsioe G. Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric 2004, 7: 78–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Windler E, Zyriax BC, Eidenmüller B, Boeing H. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study — a case-control study on women with incident coronary heart disease. Maturitas 2007, 57: 239–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000, 133: 933–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosano GM, Caixeta AM, Chierchia SL, et al. Short-term anti-ischemic effect of 17beta-estradiol in postmenopausal women with coronary artery disease. Circulation 1997, 96: 2837–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343: 522–29.PubMedCrossRefGoogle Scholar
  21. 21.
    Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297: 1465–77.PubMedCrossRefGoogle Scholar
  22. 22.
    van de Weijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007, 56: 231–48.PubMedCrossRefGoogle Scholar
  23. 23.
    Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006, 9(Suppl 11): 19–27.PubMedCrossRefGoogle Scholar
  24. 24.
    Scarabin PY, Alhenc-Gelas M, Oger E, Plu-Bureau G. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women—a randomised controlled trial. Thromb Haemost 1999, 81: 673–5.PubMedGoogle Scholar
  25. 25.
    Van Baal WM, Emeis JJ, Kenemans P, et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999, 29: 913–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Lobo RA. Menopause and stroke and the effects of hormonal therapy. Climacteric 2007, 10(Suppl 2): 27–31.PubMedCrossRefGoogle Scholar
  27. 27.
    Rosano GM, Vitale C, Fini M. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann NY Acad Sci 2006, 1092: 341–8.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2011

Authors and Affiliations

  • S. S. Signorelli
    • 1
  • S. Sciacchitano
    • 2
  • M. Anzaldi
    • 1
  • V. Fiore
    • 1
  • S. Catanzaro
    • 1
  • M. Simili
    • 1
  • S. Neri
    • 3
  1. 1.Department of Internal Medicine and Systemic Disease, Section of Internal and Vascular MedicineOspedale Garibaldi CentroCataniaItaly
  2. 2.Department of Obstetrics and Gynecological and Radiological ScienceUniversity of CataniaCataniaItaly
  3. 3.Department of Internal Medicine and Systemic Disease, Section of Internal Medicine, Faculty of MedicineUniversity of CataniaCataniaItaly

Personalised recommendations